Nebenwirkungen · Mirapexin
MIRAPEXIN 0.26 mg prolonged-release tablets MIRAPEXIN 0.52 mg prolonged-release tablets MIRAPEXIN 1.05 mg prolonged-release tablets MIRAPEXIN 1.57 mg prolonged-release tablets MIRAPEXIN 2.1 mg prolonged-release tablets MIRAPEXIN 2.62 mg prolonged-release tablets MIRAPEXIN 3.15 mg prolonged-release tablets · Abschnitt 4.8 · PDF-Seite 22
HOS-086684 · Präparat HOS-083333
Based on the analysis of pooled placebo-controlled trials, comprising a total of 1 778 Parkinson’s disease patients on pramipexole and 1 297 patients on placebo, adverse drug reactions were frequently reported for both groups. 67% of patients on pramipexole and 54% of patients on placebo reported at least one adverse drug reaction.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-29T09:14:00Z · SHA-256 10b100c75ddc71f5dd2ebff9e8c7467440f96455ec4517ce8521647f7acf11e0 · Passage 318f8750815641263f52ec0d96a7b94a034cb8896a87577d9531865eca44b2a3 · Zeichen 0–333 im Abschnitt